



Updated: 03/2026  
DMMA Approved: 04/2026

Request for Prior Authorization for Zoladex (goserelin acetate)  
Website Form – [www.highmarkhealthoptions.com](http://www.highmarkhealthoptions.com)  
Submit request via: Fax - 1-855-476-4158

All requests for Zoladex (goserelin acetate) require a Prior Authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

**\* Note: please reference the Highmark Health Options Gender Transition Services (MP-033-MD-DE) policy for all gender dysphoria requests.**

### **Zoladex (goserelin acetate) Prior Authorization Criteria:**

For all requests for Zoladex (goserelin acetate) all of the following criteria must be met:

- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- Member does not have any known contraindications to therapy
- Must be age-appropriate according to FDA-approved labeling, nationally recognized compendia, or evidence-based practice guidelines

Coverage may be provided with a diagnosis of prostate cancer

- **Initial Duration of Approval:** 12 months
- **Reauthorization criteria:**
  - Documentation of continued benefit from therapy
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided with a diagnosis of advanced breast cancer

- **Initial Duration of Approval:** 12 months
- **Reauthorization criteria:**
  - Documentation of continued benefit from therapy
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided with a diagnosis of **endometriosis** and the following criteria is met:

- Must meet one of the following diagnostic criteria:
  - Confirmed by laparoscopy
  - Complete an evaluation to exclude other causes of pelvic pain
- Must be prescribed by or in consultation with a gynecologist
- Must provide documentation showing the member has tried and failed (which will be verified via pharmacy claims if available) or had an intolerance or contraindication to ALL of the following:
  - Estrogen-progestin contraceptives, progestins, or danazol
  - NSAIDs
  - Leuprolide acetate\*
- **Maximum Duration of Approval:** 6 months

Coverage may be provided with a diagnosis of **dysfunctional uterine bleeding** and the following criteria is met:

- Must be used as an endometrial-thinning agent prior to endometrial ablation (surgery)
- Must be prescribed by or in consultation with a gynecologist
- Dose does not exceed 3.6 mg per month
- **Initial Duration of Approval:** 2 months (1 treatment course)
- **Reauthorization criteria:**
  - Documentation of the reason for delay in surgery
- **Reauthorization Duration of Approval:** 2 months (one additional treatment course; maximum of 2 courses total)

\*Leuprolide acetate may require prior authorization

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

Drugs are authorized in generic form unless the branded product is on the preferred drug list or the prescriber has indicated in writing that the branded product is medically necessary. If only the branded product is on the preferred drug list, the generic form will be considered non-preferred and shall not require the prescriber to indicate in writing that the branded product is medically necessary.

**ZOLADEX (GOSERELIN ACETATE)  
PRIOR AUTHORIZATION FORM**

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. **FAX: (855) 476-4158**  
If needed, you may call to speak to a Pharmacy Services Representative. **PHONE: (844) 325-6251 Mon – Fri 8 am to 7 pm**

**PROVIDER INFORMATION**

Requesting Provider:	NPI:
Provider Specialty:	Office Contact:
Office Address:	Office Phone:
	Office Fax:

**MEMBER INFORMATION**

Member Name:	DOB:
Member ID:	Member weight:      Height:

**REQUESTED DRUG INFORMATION**

Medication:	Strength:
Directions:	Quantity:      Refills:
Is the member currently receiving requested medication? <input type="checkbox"/> Yes <input type="checkbox"/> No      Date Medication Initiated:	
Is this medication being used for a chronic or long-term condition for which the medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No	

**Billing Information**

This medication will be billed:  at a pharmacy **OR**  medically, JCODE:  
Place of Service:  Hospital     Provider's office     Member's home     Other

**Place of Service Information**

Name:	NPI:
Address:	Phone:

**MEDICAL HISTORY (Complete for ALL requests)**

Diagnosis:	ICD Code:
<b>Endometriosis:</b> Has the diagnosis been confirmed by laparoscopy or has a complete evaluation to exclude other causes of pelvic pain been performed? <input type="checkbox"/> Yes <input type="checkbox"/> No (must provide chart documentation of an evaluation to exclude other diagnoses)	
Has the member tried and failed any of the following? Please list below: <input type="checkbox"/> NSAIDs <input type="checkbox"/> Contraceptives, progestins, or danazol <input type="checkbox"/> Leuprolide acetate	
<b>Dysfunctional uterine bleeding:</b> Is this being used prior to endometrial ablation? <input type="checkbox"/> Yes <input type="checkbox"/> No	

**CURRENT or PREVIOUS THERAPY**

Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)

**REAUTHORIZATION**

**Prostate and breast cancer:** Does the member continue to benefit from therapy?  Yes  No  
**Endometriosis:** Provide the reason for retreatment:  
**Dysfunctional uterine bleeding:** Provide the reason for delay in surgery:

**SUPPORTING INFORMATION or CLINICAL RATIONALE**

**Prescribing Provider Signature**

**Date**

--	--



Updated: 03/2026  
DMMA Approved: 04/2026



Updated: 03/2026  
DMMA Approved: 04/2026